SecBot SecBot
144 ·Filed Nov 10, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizondays Processed6d 11h ago SEC0001957799-26-000200
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The proposed sale is small relative to market cap and the insider's holdings. The insider has been a consistent seller in recent weeks, but the amounts are not large enough to signal a change in outlook. Monitor for any acceleration in insider selling or a Form 4 filing confirming the transaction.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$314.16
T+0 close · Nov 10, 2026 · via day close
Latest settled
+0.85%
T+1 · $316.83
Vs SPY
−0.47%
α at T+1
Next horizon
T+5
in 5h
  1. T+0 · Nov 10 $314.16entry
  2. T+1 · 6d ago +0.85%α −0.47% · $316.83
  3. T+4 · todayOpen
  4. T+5 · in 5h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Jason Aryeh filed a Form 144 notice to sell 3,000 shares of Ligand Pharmaceuticals Class B common stock, with an estimated aggregate market value of approximately $960,084. The shares were acquired in 2019 via secondary market purchases. This is a relatively small sale relative to the company's $6.1B market cap and the insider's apparent holdings, and the filing signals intent to sell rather than a completed transaction.

Key Facts

  • Director Jason Aryeh filed Form 144 to sell 3,000 shares of Class B common stock
  • Estimated aggregate market value of the proposed sale is $960,084.19
  • Shares were acquired between May 14, 2019 and July 30, 2019 via secondary market purchases
  • The proposed sale date is November 10, 2026 on Nasdaq
  • The insider has sold 2,193 shares in three separate transactions between October 30 and November 4, 2026, totaling approximately $671,558

Financial Impact

Proposed sale of 3,000 shares valued at ~$960K, representing a small fraction of the insider's apparent holdings and less than 0.02% of the company's $6.1B market cap

dilution

Risk Factors

  • Form 144 is only an intent to sell; the sale may not be executed
  • The insider has sold shares in multiple transactions over the past two weeks, which could indicate a pattern of routine portfolio diversification

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001957799-26-000200
Document: 0001957799-26-000200-index.html0001957799-26-000200
Document: 0001957799-26-000200.txt0001957799-26-000200

Track record

29 reports on LGND

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
  6. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
  7. Nov 10, 20266d ago 144 Neutral 2/10 Viewing Entry $314.16 Now $301.71 −3.96% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
  9. Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
  10. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026